Last reviewed · How we verify
Difluprednate Eye Drops
At a glance
| Generic name | Difluprednate Eye Drops |
|---|---|
| Sponsor | Kafrelsheikh University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction II (PHASE3)
- A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration (PHASE1, PHASE2)
- Steroids and Cross-linking for Ulcer Treatment (PHASE3)
- Difluprednate vs. a Prednisolone Acetate - Phenylephrine on Post-operative Inflammation Following Cataract Surgery. (PHASE4)
- A Study of the Effect of Different Doses of Difluprednate Eye Drops on the Intraocular Pressure After Phacoemulsification (PHASE4)
- Clinical Investigation of the Dextenza 0.4mg Intracanalicular Insert Delivery System Used in Cataract Surgery (PHASE4)
- Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis (PHASE4)
- Macular Edema Nepafenac vs. Difluprednate Uveitis Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Difluprednate Eye Drops CI brief — competitive landscape report
- Difluprednate Eye Drops updates RSS · CI watch RSS
- Kafrelsheikh University portfolio CI